The variables included TGF-β score, CD47, other immune markers known to have an immunosuppressive role in the stroma: CXCL12, BAG2, CXCR4, BRD4, HMGA2, CSF1R, CD276, VTCN1, some previously reported to be associated with ICB response CD274, CTLA4, VTCN1, estimated immune cell abundance from RNAseq analysis (N = 9), and clinical-pathological features: age, gender, microsatellite instability (MSI) status, body mass index (BMI), disease type as endometrial, ovarian, or cervical cancer, histology type as endometrioid, serous, or squamous, and treatment cycle count (Fig. 1F). This evidence concerns the gene VTCN1 and cervical cancer.